Search Clinical Trials
Thank you for your interest in research at UTMB! Taking part in research is one way to be part of tomorrow’s healthcare discoveries. UTMB is always looking for volunteers just like you so that our researchers can better understand how to prevent, diagnose, and treat diseases. Everyone is needed. Both healthy volunteers and people with health conditions can help us answer important questions that impact the health of our communities. Ready to start searching for a study to be involved with? • Enter a health condition or leave it blank if you are looking to join any study as a healthy volunteer • Enter your gender and age • Click “View Results” • Click on the study titles for information • Click on the “Contact/Details” tab to get information for contacting the study team
Sponsor Condition of Interest |
---|
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy...
NRG Oncology
Breast Cancer
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian
function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in
improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage
breast cancer (EBC) patients with estrogen... expand
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients). Type: Interventional Start Date: Aug 2023 |
THRIVE Well Cancer FDTN/Exercise_Creatine Supplementation
The University of Texas Medical Branch, Galveston
Breast Cancer
Breast Cancer Female
Muscle Weakness
The study's purpose is to evaluate whether creatine supplementation can help breast
cancer survivors respond quicker to exercise by improving strength, endurance, and body
composition. We are seeking to compare information collected from healthy woman of the
same age who have never had breast cancer... expand
The study's purpose is to evaluate whether creatine supplementation can help breast cancer survivors respond quicker to exercise by improving strength, endurance, and body composition. We are seeking to compare information collected from healthy woman of the same age who have never had breast cancer to those participants who have had breast cancer and undergone chemotherapy treatment. Type: Interventional Start Date: Aug 2024 |
CCT-102 or Expectant Management in Delayed Pregnancy Loss
Conceptra Biosciences, LLC
Early Pregnancy Loss, Delayed Pregnancy Loss
A Phase 3, multi-center clinical trial of a CCT-102 regimen or expectant management to
promote uterine evacuation in first trimester non-progressing Delayed Pregnancy Loss
(DPL). expand
A Phase 3, multi-center clinical trial of a CCT-102 regimen or expectant management to promote uterine evacuation in first trimester non-progressing Delayed Pregnancy Loss (DPL). Type: Interventional Start Date: Jul 2023 |
Pulsed Field Ablation (PFA) vs Anti-Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent...
Boston Scientific Corporation
Persistent Atrial Fibrillation
The purpose of this study is to establish the safety and effectiveness of pulsed field
ablation as a first-line ablation treatment for subjects with persistent atrial
fibrillation as compared to subjects who received an initial treatment with
anti-arrhythmic drugs. expand
The purpose of this study is to establish the safety and effectiveness of pulsed field ablation as a first-line ablation treatment for subjects with persistent atrial fibrillation as compared to subjects who received an initial treatment with anti-arrhythmic drugs. Type: Interventional Start Date: Dec 2023 |
Blinded Efficacy and Safety Study of CAL02 IV Plus SOC in Subjects With Severe Community-Acquired Bacterial...
Eagle Pharmaceuticals, Inc.
Pneumonia, Bacterial
This is a placebo-controlled study to evaluate the addition of CAL02 to standard of care
in treating hospitalized subjects diagnosed with severe community acquired bacterial
pneumonia (SCABP) requiring critical care measures expand
This is a placebo-controlled study to evaluate the addition of CAL02 to standard of care in treating hospitalized subjects diagnosed with severe community acquired bacterial pneumonia (SCABP) requiring critical care measures Type: Interventional Start Date: Jul 2023 |
Healthy Communities Through CHW Initiatives
The University of Texas Medical Branch, Galveston
Diabetes Mellitus, Type 2
Diabetes Mellitus Risk
Latino(a)s suffer from poor social determinants of health (SODH) conditions more than
non-minority populations, and being a minority is risk factor alone for diabetes. In the
proposed study, investigators will assist church members in becoming Community Health
Workers (CHWs), train them in diabetes,... expand
Latino(a)s suffer from poor social determinants of health (SODH) conditions more than non-minority populations, and being a minority is risk factor alone for diabetes. In the proposed study, investigators will assist church members in becoming Community Health Workers (CHWs), train them in diabetes, and to track the ability to address healthcare access and quality barriers using an online platform. Type: Interventional Start Date: Aug 2023 |
The Effect of Clinic Visit Audio Recordings for Self-management in Older Adults
Dartmouth-Hitchcock Medical Center
Diabetes
The objective of this study is to conduct a multisite trial evaluating the impact of
adding an audio recording of clinic visits (AUDIO) to usual care in older adults with
multimorbidity, including diabetes, compared to After Visit Summary (AVS) alone (Usual
Care; UC). expand
The objective of this study is to conduct a multisite trial evaluating the impact of adding an audio recording of clinic visits (AUDIO) to usual care in older adults with multimorbidity, including diabetes, compared to After Visit Summary (AVS) alone (Usual Care; UC). Type: Interventional Start Date: Dec 2023 |
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in...
National Cancer Institute (NCI)
Anatomic Stage IV Breast Cancer AJCC v8
Invasive Breast Carcinoma
Metastatic Triple-Negative Breast Carcinoma
This phase II trial studies how well nab-paclitaxel, durvalumab, and tremelimumab with or
without personalized synthetic long peptide vaccine (neoantigen vaccine) works in
treating patients with triple negative breast cancer that has spread from where it first
started (primary site) to other places... expand
This phase II trial studies how well nab-paclitaxel, durvalumab, and tremelimumab with or without personalized synthetic long peptide vaccine (neoantigen vaccine) works in treating patients with triple negative breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Chemotherapy drugs, such as nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as durvalumab and tremelimumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. It is not yet known whether giving nab-paclitaxel, durvalumab, and tremelimumab with or without neoantigen vaccine will work better in treating patients with triple negative breast cancer. Type: Interventional Start Date: Apr 2021 |
Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
Duke University
Lactating Women on Select DOI
Breastfed Infants of Mothers on Select DOI
Over half of women in the US who are breastfeeding their infants take prescription drugs.
You are being asked to participate in this study because you are breastfeeding your
infant and are currently taking, as part of your medical care, at least one of the drugs
we are studying. We are interested... expand
Over half of women in the US who are breastfeeding their infants take prescription drugs. You are being asked to participate in this study because you are breastfeeding your infant and are currently taking, as part of your medical care, at least one of the drugs we are studying. We are interested in studying drugs commonly prescribed to women who are breastfeeding so we can learn more about the amount of drug that is transferred to breastmilk and estimate how much of drug that is consumed by breastfed infants. Type: Observational Start Date: Oct 2018 |
Low-Dose Versus High-Dose Oxytocin Dosing for Induction and Augmentation of Labor
The University of Texas Medical Branch, Galveston
Labor Long
The goal of this clinical trial is to compare oxytocin infusion rates for induction and
augmentation of labor in nulliparous women. The main question[s] it aims to answer are:
- Does a high dose oxytocin infusion protocol affect length of induction to delivery
interval?
- Does a high... expand
The goal of this clinical trial is to compare oxytocin infusion rates for induction and augmentation of labor in nulliparous women. The main question[s] it aims to answer are: - Does a high dose oxytocin infusion protocol affect length of induction to delivery interval? - Does a high dose oxytocin infusion protocol affect mode of delivery? - Does a high dose oxytocin infusion protocol affect maternal and neonatal outcomes? Participants will be randomized to either low- or high-dose oxytocin groups: - The low dose group will receive an infusion to start at 2 milli-units/min and will be increased by 2 milli-units/min every 20 minutes. The maximum rate of infusion is 40 milli-units/min. - The high dose group will receive an infusion to start at 6 milli-units/min and will be increased by 6 milli-units/min every 20 minutes. Maximum rate of infusion is 40 milli-units/min. Type: Interventional Start Date: Apr 2023 |
Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab)...
National Cancer Institute (NCI)
Head and Neck Squamous Cell Carcinoma
Metastatic Head and Neck Squamous Cell Carcinoma
Metastatic Hypopharyngeal Squamous Cell Carcinoma
Metastatic Laryngeal Squamous Cell Carcinoma
Metastatic Oral Cavity Squamous Cell Carcinoma
This phase II trial compares the effect of adding ipatasertib to pembrolizumab (standard
immunotherapy) vs. pembrolizumab alone in treating patients with squamous cell cancer of
the head and neck that has come back (recurrent) or that has spread from where it first
started (primary site) to other... expand
This phase II trial compares the effect of adding ipatasertib to pembrolizumab (standard immunotherapy) vs. pembrolizumab alone in treating patients with squamous cell cancer of the head and neck that has come back (recurrent) or that has spread from where it first started (primary site) to other places in the body (metastatic). Ipatasertib is in a class of medications called protein kinase B (AKT) inhibitors. It may stop the growth of tumor cells and may kill them. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving ipatasertib in combination with pembrolizumab may be more effective than pembrolizumab alone in improving some outcomes in patients with recurrent/metastatic squamous cell cancer of the head and neck. Type: Interventional Start Date: Jul 2022 |
Understanding the Long-term Impact of COVID on Children and Families
NYU Langone Health
SARS-CoV-2 Infection
This is a combined retrospective and prospective, longitudinal, observational meta-cohort
of individuals age 0-25 years who will enter the cohort with and without SARS-CoV-2
infection at varying stages before and after infection. Individuals with and without
SARS-CoV-2 infection and with or without... expand
This is a combined retrospective and prospective, longitudinal, observational meta-cohort of individuals age 0-25 years who will enter the cohort with and without SARS-CoV-2 infection at varying stages before and after infection. Individuals with and without SARS-CoV-2 infection and with or without PASC symptoms will be followed to identify risk factors and occurrence of PASC. This study will be conducted in the United States and participants will be recruited through inpatient, outpatient, and community-based settings. Study data including age, demographics, social determinants of health, medical history, vaccination history, details of acute SARS-CoV-2 infection, overall health and physical function, and PASC symptoms will be reported by participants or collected from the electronic health record using a case report form at specified intervals. Biologic specimens will be collected at specified intervals, with some tests performed in local clinical laboratories and others performed by centralized research centers or banked in the Biospecimen Repository. Advanced clinical examinations and radiologic examinations will be performed at local study sites with cross-site standardization. Type: Observational Start Date: Mar 2022 |
A Trial of Pessary and Progesterone for Preterm Prevention in Twin Gestation With a Short Cervix
The George Washington University Biostatistics Center
Short Cervical Length
This protocol outlines a randomized trial of 630 women evaluating the use of micronized
vaginal progesterone or pessary versus control (placebo) to prevent early preterm birth
in women carrying twins and with a cervical length of less than 30 millimeters. expand
This protocol outlines a randomized trial of 630 women evaluating the use of micronized vaginal progesterone or pessary versus control (placebo) to prevent early preterm birth in women carrying twins and with a cervical length of less than 30 millimeters. Type: Interventional Start Date: Nov 2015 |
Longitudinal Study of the Porphyrias
Icahn School of Medicine at Mount Sinai
Acute Porphyrias
Cutaneous Porphyrias
The objective of this protocol is to conduct a longitudinal multidisciplinary
investigation of the human porphyrias including the natural history, morbidity, pregnancy
outcomes, and mortality in people with these disorders. expand
The objective of this protocol is to conduct a longitudinal multidisciplinary investigation of the human porphyrias including the natural history, morbidity, pregnancy outcomes, and mortality in people with these disorders. Type: Observational Start Date: Nov 2010 |
Prospective Analysis to Detect Myometrial Cells in Peritoneal Washing in Patients Undergoing Minimally...
The University of Texas Medical Branch, Galveston
Hysterectomy
The Aim of the study is to determine endometrial/myometrial spillage during total
laparoscopic hysterectomy with manual morcellation. expand
The Aim of the study is to determine endometrial/myometrial spillage during total laparoscopic hysterectomy with manual morcellation. Type: Observational Start Date: Aug 2023 |
Above-Knee-High Application of Lower Limb Compression and Its Impact on Clinical Outcome in Patients...
The University of Texas Medical Branch, Galveston
Heart Failure; With Decompensation
Lower Extremity Edema
Heart Failure,Congestive
Heart failure (HF) remains one of the most common causes of hospitalization with high
morbidity and mortality, and its worldwide prevalence is increasing. Despite notable
progress in outcomes for HF the rate of early rehospitalization for HF (re-HHF) remains
high, especially in the first 30 days.... expand
Heart failure (HF) remains one of the most common causes of hospitalization with high morbidity and mortality, and its worldwide prevalence is increasing. Despite notable progress in outcomes for HF the rate of early rehospitalization for HF (re-HHF) remains high, especially in the first 30 days. The rate of 30-day HF rehospitalization in the claims databases of the USA and in worldwide randomized clinical trials is 20-25% and 5-10% respectively. In patients with bilateral leg edema, the presence of CHF (congestive heart failure) as the factor causing or worsening local leg swelling should be evaluated. Application of local leg compression can be considered in stable CHF patients without decompensated heart function (NYHA Class I and II) for both CHF-related edema treatment and for treatment of concomitant diseases leading to leg swelling occurrence. Current literature does not have recommendations on the routine use of lower limb compression in leg swelling related to end stage heart disease and advanced, decompensated heart failure. Potential benefits of applying medical compression in more severe classes of CHF (NYHA Class III and IV) would need to be evaluated by further randomized clinical studies to determine which cohort of patients would benefit most from lower limb compression, as well as to choose the safest and most efficient compression protocol for these patients. The AIM of this study is to improve the clinical outcome of patients admitted with exacerbation of heart failure with associated volume overload. The primary objectives are: 1) diminish the duration of hospitalization of CHF patients; 2) decrease the incidence of rehospitalization from CHF exacerbation and 3) prevent local complications associated with prolonged lower extremity edema. The investigators hypothesize that the application of local compression to bilateral lower extremities, when added to guideline-based therapy for CHF exacerbation, will improve overall clinical outcome in patients at the University of Texas Medical Branch (UTMB). If our intervention is proven to be beneficial, it could lead to a significant reduction in nationwide hospitalization costs associated with heart failure. Type: Interventional Start Date: Apr 2022 |
MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
Vertos Medical, Inc.
Lumbar Spinal Stenosis
This prospective longitudinal study will compare incidence rates of Medicare beneficiary
surgical and minimally invasive intervention post index procedure, as well as harms
associated with the MILD procedure, at 24 months post-treatment with MILD, tested against
a control group of similar patients... expand
This prospective longitudinal study will compare incidence rates of Medicare beneficiary surgical and minimally invasive intervention post index procedure, as well as harms associated with the MILD procedure, at 24 months post-treatment with MILD, tested against a control group of similar patients that have had a comparable procedure. This study will start with patients treated with a study procedure having an index date on or after January 1, 2017, and enrollment will continue until stopped by the sponsor. Type: Observational Start Date: Mar 2017 |
Low Frequency Ultrasound for Osteoarthritis Healing and Rehabilitation
The University of Texas Medical Branch, Galveston
Osteo Arthritis Knee
Age Related Osteoporosis
Pain
Knee Joint Contracture
The purpose of this study is to determine the safety and effectiveness (how well it
works) of a new experimental ultrasound bath device that uses low frequency ultrasound
(LFU) that may or may not help healing. expand
The purpose of this study is to determine the safety and effectiveness (how well it works) of a new experimental ultrasound bath device that uses low frequency ultrasound (LFU) that may or may not help healing. Type: Interventional Start Date: Jul 2024 |
A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)
Janssen Research & Development, LLC
Hemolytic Disease of the Fetus and Newborn
The purpose of this study is to assess the effectiveness of nipocalimab when compared to
placebo in decreasing the risk of fetal anemia (a condition in which a baby's red blood
cell volume falls below normal levels while the baby is developing in the womb) with live
neonates in pregnant participants... expand
The purpose of this study is to assess the effectiveness of nipocalimab when compared to placebo in decreasing the risk of fetal anemia (a condition in which a baby's red blood cell volume falls below normal levels while the baby is developing in the womb) with live neonates in pregnant participants at risk for severe hemolytic disease of the fetus and newborn. Type: Interventional Start Date: Dec 2023 |
A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction...
Eli Lilly and Company
Heart Failure
Heart Failure With Preserved Ejection Fraction
The main purpose of this study is to assess the efficacy and safety of LY3540378 in
adults with worsening heart failure with preserved ejection fraction expand
The main purpose of this study is to assess the efficacy and safety of LY3540378 in adults with worsening heart failure with preserved ejection fraction Type: Interventional Start Date: Feb 2023 |
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants...
Janssen Research & Development, LLC
Urinary Bladder Neoplasms
The purpose of study is to compare bladder intact-event free survival (BI-EFS) in
participants receiving TAR-200 in combination with intravenous (IV) cetrelimab versus
concurrent chemoradiotherapy. expand
The purpose of study is to compare bladder intact-event free survival (BI-EFS) in participants receiving TAR-200 in combination with intravenous (IV) cetrelimab versus concurrent chemoradiotherapy. Type: Interventional Start Date: Dec 2020 |
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive...
Alliance for Clinical Trials in Oncology
Anatomic Stage IA Breast Cancer AJCC v8
Anatomic Stage II Breast Cancer AJCC v8
Anatomic Stage IIA Breast Cancer AJCC v8
Anatomic Stage IIB Breast Cancer AJCC v8
Anatomic Stage III Breast Cancer AJCC v8
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in
preventing breast cancer from coming back (relapsing) in patients with high risk, HER2
positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a
chemotherapy drug, called DM1. Trastuzumab... expand
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone. Type: Interventional Start Date: Jan 2021 |
Nodify XL2 Classifier Clinical Utility Study in Low to Moderate Risk Lung Nodules
Biodesix, Inc.
Nodule Solitary Pulmonary
Non-small Cell Carcinoma
This study evaluates the how addition of the Nodify XL2 test result impacts the clinical
management of newly identified solid lung nodules assessed as low to moderate risk of
cancer. expand
This study evaluates the how addition of the Nodify XL2 test result impacts the clinical management of newly identified solid lung nodules assessed as low to moderate risk of cancer. Type: Observational Start Date: Dec 2020 |
Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed,...
National Cancer Institute (NCI)
Lung Adenocarcinoma
Lung Large Cell Carcinoma
Lung Non-Squamous Non-Small Cell Carcinoma
Stage III Lung Cancer AJCC v8
This phase II trial tests whether TRC102 (methoxyamine hydrochloride) in combination
usual care treatment comprised of pemetrexed, cisplatin or carboplatin, and radiation
therapy followed by durvalumab works better than the usual care treatment alone to shrink
tumors in patients with stage III non-squamous... expand
This phase II trial tests whether TRC102 (methoxyamine hydrochloride) in combination usual care treatment comprised of pemetrexed, cisplatin or carboplatin, and radiation therapy followed by durvalumab works better than the usual care treatment alone to shrink tumors in patients with stage III non-squamous non-small cell lung cancer (NSCLC). TRC102 is in a class of drugs called antineoplastic agents. It blocks the ability of a cell to repair damage to its DNA and may kill cancer cells. It may also help some anticancer drugs work better. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make DNA and may kill cancer cells. Chemotherapy drugs, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy sources to kill tumor cells and shrink tumors. Giving TRC102 in combination with usual care treatment may be more effective than usual care treatment alone in stabilizing and lengthening survival time in patients with stage III non-squamous NSCLC. Type: Interventional Start Date: Dec 2022 |
PCORI-CER-1306-03385 Lung Cancer Screening Decision Aid Development and Testing
M.D. Anderson Cancer Center
Health Knowledge, Attitudes, Practice
Objectives:
This protocol addresses the first phase of a larger project funded by the
Patient-Centered Outcomes Research Institute to help heavy smokers make informed
decisions about lung cancer screening with low-dose computed tomography (CT). A separate
IRB protocol will be submitted for the... expand
Objectives: This protocol addresses the first phase of a larger project funded by the Patient-Centered Outcomes Research Institute to help heavy smokers make informed decisions about lung cancer screening with low-dose computed tomography (CT). A separate IRB protocol will be submitted for the larger, comparative study. In this initial development phase, our prototype patient decision aid will be updated to reflect current guidelines about lung cancer screening. The updated aid will then be pilot-tested in a new sample of patients. In addition, several of the study measures will be refined and further developed in preparation for the larger study. The specific aims of the measures and decision aid development phase of this project are as follows: Update the aid to reflect current screening guidelines and refine the aid via cognitive testing with patients/smokers; and pilot test the updated aid for acceptability with patients/smokers. Modify our current measure of lung cancer knowledge, conduct cognitive testing of the new measure with patients/smokers, and evaluate the reliability of the new measure in a sample patients/smokers. Type: Observational Start Date: Jul 2014 |
- Previous
- Next